Indomethacin treatment of patent ductus arteriosus in premature infants

Paediatric and Perinatal Drug Therapy

Volumn 4, Issue 3, 2001, Pages 85-91

  McIntyre, John ^a   Van Overmeire, Bart ^a   Van den Anker, John N ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Ductus arteriosus, patent; Indomethacin; Infant, premature

Indexed keywords

ACETYLSALICYLIC ACID; ARGIPRESSIN; CREATININE; ELECTROLYTE; ETAMSYLATE; IBUPROFEN; INDOMETACIN; MEFENAMIC ACID; OXYGEN; PLASMA PROTEIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; RENIN; SODIUM; SULINDAC; UREA;

BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; CHYLOTHORAX; CLINICAL TRIAL; DOPPLER ECHOGRAPHY; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; ECHOCARDIOGRAPHY; ELECTROLYTE DISTURBANCE; HUMAN; HYPERTENSION; INCIDENCE; INTESTINE PERFORATION; KIDNEY DYSFUNCTION; LEUKOMALACIA; META ANALYSIS; NEAR INFRARED SPECTROSCOPY; NECROTIZING ENTEROCOLITIS; OLIGURIA; PATENT DUCTUS ARTERIOSUS; PNEUMOTHORAX; PREMATURITY; REVIEW; VOCAL CORD PARALYSIS; WOUND INFECTION;

EID: 0035746417     PISSN: 14630095     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Permanent anatomic closure of the ductus arteriosus in newborn baboons: The roles of postnatal constriction, hypoxia, and gestation
2. Regulation of ductus arteriosus patency by nitric oxide in fetal lambs: The role of gestation, oxygen tension, and vasa vasorum
3. Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment
4. Intermittent ductal patency in healthy newborn infants: Demonstration by colour Doppler flow mapping
5. Evaluation of the preterm infant for patent ductus arteriosus
6. Prophylactic indomethacin: Factors determining permanent ductus arteriosus closure
7. Patent ductus arteriosus complicating the respiratory distress syndrome in preterm infants
8. Incidence and clinical features of patent ductus arteriosus in low-birthweight infants: A prospective analysis of 150 consecutively born infants
9. Increased risk of bronchopulmonary dysplasia in infants with patent ductus arteriosus
10. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis
11. Pharmacologic closure of patent ductus arteriosus in the premature infant
12. Effects of indomethacin in premature infants with patent ductus arteriosus: Results of a national collaborative study
13. Pharmacokinetics of indomethacin
14. Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man
15. Gestational age and indomethacin elimination in the neonate
16. Pharmacokinetics of intravenously administered indomethacin in premature infants
17. The disposition of indomethacin in preterm babies
18. Pharmacokinetics of indomethacin in the neonate. Relation of plasma indomethacin levels to response of the ductus arteriosus
19. Indomethacin pharmacokinetics in neonates: The value of volume of distribution as a marker of permanent patent ductus arteriosus closure
20. Population pharmacokinetics of intravenous indomethacin in neonates with symptomatic patent ductus arteriosus
21. Intravenous indomethacin for patent ductus arteriosus
22. Response of the patent ductus arteriosus to indomethacin treatment
23. Introduction of plasma indomethacin level monitoring and evaluation of an effective threshold level in very low birth weight infants with symptomatic patent ductus arteriosus
24. Indomethacin therapy of patent ductus in preterm infants controlled by plasma levels
25. Indomethacin therapy in premature infants with patent ductus arteriosus - Determination of therapeutic plasma levels
26. Pharmacokinetics of intra-arterial indomethacin treatment for patent ductus arteriosus
27. Indomethacin for patent ductus arteriosus closure. Application of serum concentrations and pharmacodynamics to improve response
28. Is surgical ligation of a patent ductus arteriosus the preferred initial approach for the neonate with extremely low birth weight?
29. Optimal management of patent ductus arteriosus in the neonate weighing less than 800 g
30. Management of patent ductus arteriosus: A comparison of operative v pharmacologic treatment
31. Indomethacin versus immediate ligation in the treatment of 82 newborns with patent ductus arteriosus
32. Recommendations for the postnatal use of indomethacin: An analysis of four separate treatment strategies
33. Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants
34. Prophylactic indomethacin: Systematic review and meta-analysis
35. Low-dose indomethacin and prevention of intraventricular hemorrhage: A multicenter randomized trial
36. Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus
37. Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity
38. Effects of prolonged versus acute indomethacin therapy in very low birth-weight infants with patent ductus arteriosus
39. Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants
40. The effect of indomethacin on cerebral blood-flow velocity in premature infants
41. Cerebral blood flow following indomethacin administration
42. Effect of infusion rate of indomethacin on cerebrovascular responses in preterm neonates
43. Effect of indomethacin on cerebral blood flow velocities in very low birth weight neonates with a patent ductus arteriosus
44. Continuous versus multiple rapid infusions of indomethacin: Effects on cerebral blood flow velocity
45. Effects of repeated indomethacin administration on cerebral oxygenation and haemodynamics in preterm infants: Combined near infrared spectrophotometry and Doppler ultrasound study
46. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus
47. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus
48. Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants
49. Indomethacin reduces the risks of severe intraventricular hemorrhage
50. Outcome of children in the indomethacin intraventricular haemorrhage prevention trial
51. Indomethacin treatment decreases renal blood flow velocity in human neonates
52. Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging
53. Effect of prolonged indomethacin therapy on renal function and selected vasoactive hormones in very-low-birth-weight infants with symptomatic patent ductus arteriosus
54. The effects of indomethacin on renal function and intracranial hemorrhage in infants with patent ductus arteriosus
55. Furosemide prevents the renal side effects of indomethacin therapy in premature infants with patent ductus arteriosus
56. Furosemide in indomethacin-treated infants - Systematic review and meta-analysis
57. Can dopamine prevent the renal side effects of indomethacin? A prospective randomized clinical study
58. Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin
59. Localized intestinal perforations after enteral administration of indomethacin in premature infants
60. Effect of indomethacin on superior mesenteric artery blood flow velocity in preterm infants
61. Gut blood flow velocities in the newborn: Effects of patent ductus arteriosus and parenteral indomethacin
62. Indomethacin disposition and indomethacin-induced platelet dysfunction in premature infants
63. Pharmacokinetics of mefenamic acid in preterm infants with patent ductus arteriosus
64. Prevention of symptomatic patent ductus arteriosus with ethamsylate in babies treated with exogenous surfactant
65. Comparing sulindac with indomethacin for closure of ductus arteriosus in preterm infants
66. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants
67. Treatment of patent ductus arteriosus with ibuprofen
68. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus
69. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus